Keeping the umbilical cord long and milking may be an effective method for improving Hb and iron stores at 6 months of age in term-infants.

Premature infants especially those with birth weight <1500 g suffer from Anaemia of prematurity (AOP) and associated problems. Erythropoietin therapy is a safe effective way to prevent and to treat anaemia of prematurity. To evaluate the effect of short term administration of recombinant human erythropoietin (rHuEPO) with iron and folic acid in very low birth weight (VLBW) neonates in the prevention of anaemia of prematurity. A randomized controlled trial was carried out at Dhaka Shishu Hospital. Sixty preterm very low birth weight (PTVLBW) babies were enrolled in this study. Thirty were assigned to rHuEPO group and 30 as control. Baseline haematologic values were estimated before administration of rHuEPO. From day 7 of life rHuEPO-200

Background: Objective of the study was to find SSI rate following Caesarean section and Analysis of risk factors. Methods: This prospective randomized study carried out on 1504 patients, their demographic information, risk factors and surgical indications were recorded. Postoperatively patients were monitored for signs of SSI. Results: Out of 1504 patients, 13% developed SSI, Hospital stay, wound class, ASA class, antibiotic prophylaxis and Type of caesarean showed significant association with SSI. Conclusions: Reason for incidence of SSI higher than developed countries being only tertiary care hospital dealing with high risk pregnancies, late referrals from peripheries, Prolonged hospital stay, heavy rush of attendants, faulty supervision where dose of antibiotics is actually missed, no proper segregation of cases. Deep incisional SSIInfection occurs within 30 days after operation if no implant is left in place or within one year if implant is in place and the infection appears to be related to the operation and infection involves deep soft tissues of the incision and at least one of the following:

No abstract

Background: Thyroid disorders are among the most common endocrine disorders in pregnancy.signs and symptoms of SCH are variable, often asymptomatic. Mostly SCH is a laboratory diagnosis; Risk factors include personal or family history of thyroid dysfunction, advanced maternal age, diabetes, other autoimmune disorders and morbid obesity. Objective: To investigate the outcome of pregnancy in women detected to have subclinical hypothyroidism in early gestation and to evaluate whether treatment of subclinical hypothyroidism reduces the adverse pregnancy outcome. Methods: A total of 200 subclinical hypothyroid pregnant women in their first trimester of pregnancy (TSH> 2.5-6mU/L) were included in the study.Out of these 100 women received treatment with thyroxine (group A) and 100 were left untreated and acted as controls (groupB). Results: The mean age of both the groups was 25 years.In obstetric score; most of the women were primigravida. Antenatal complications like GDM, PIH ,small for gestational age and preterm delivery were observed almost equally.In the mode of delivery,67 women in the treated group and 78 women in the control group delivered vaginally at term.Majority of newborns in both the groups had birth weight in the range of >2.5to<3.5 kg. Conclusion: In pregnant women with SCH (TSH >2.5-6mU/L and normal T4 level) , treatment with thyroxine does not have any association in reducing the incidence of preterm labour, gestational diabetes or hypertension.Neonatal outcome was normal in both the groups.